Abstract
Objective: To evaluate the effectiveness of sucralfate in influencing throat pain, otalgia, analgesic requirement, bleeding, mucosal recovery, and incidence of postoperative bleeding in patients undergoing uvulopalatopharyngoplasty. Design: A prospective double-blind randomized study. Setting: University-affiliated tertiary referral hospital. Participants: Eighty adult patients with obstructive sleep apnea syndrome requiring uvulopalatopharyngoplasty were recruited and randomly allocated into either a sucralfate treatment group or a control group. Interventions: All patients underwent uvulopalatopharyngoplasty. Patients enrolled in the sucralfate group (n=40) were instructed to gargle the sucralfate suspension and then to swallow. Patients enrolled in the control group (n=40) were instructed to gargle placebo suspension at the same doses and schedule. Main Outcome Measures: Postoperative throat pain, otalgia, amount of analgesic required, degree of strength (defined as patients' general well-being and return to regular daily activities), percentage of mucosal covering, and postoperative bleeding. Results: Throat pain and otalgia occurred significantly less often in sucralfate group, with less analgesic requirement and with rapid mucosal healing and early return to regular daily activities. There was no significant difference in episodes of postoperative bleeding between the 2 groups (P=.37). Conclusions: Although sucralfate therapy may not provide complete analgesia after uvulopalatopharyngoplasty, it may reduce the amount of analgesic required, thus preventing dose-related adverse effects from the analgesic agent. It can also significantly reduce the total number of days needed to return to normal daily activities (P=.41).
| Original language | English |
|---|---|
| Pages (from-to) | 1082-1085 |
| Number of pages | 4 |
| Journal | Archives of Otolaryngology - Head and Neck Surgery |
| Volume | 132 |
| Issue number | 10 |
| Publication status | Published - 2006 Oct 25 |
Fingerprint
ASJC Scopus subject areas
- Otorhinolaryngology
Cite this
Efficacy of sucralfate in the postoperative management of uvulopalatopharyngoplasty : A double-blind, randomized, controlled study. / Zodpe, Prakash; Cho, Jae-Gu; Kang, Hee Joon; Hwang, Soon Jae; Lee, Heung Man.
In: Archives of Otolaryngology - Head and Neck Surgery, Vol. 132, No. 10, 25.10.2006, p. 1082-1085.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Efficacy of sucralfate in the postoperative management of uvulopalatopharyngoplasty
T2 - A double-blind, randomized, controlled study
AU - Zodpe, Prakash
AU - Cho, Jae-Gu
AU - Kang, Hee Joon
AU - Hwang, Soon Jae
AU - Lee, Heung Man
PY - 2006/10/25
Y1 - 2006/10/25
N2 - Objective: To evaluate the effectiveness of sucralfate in influencing throat pain, otalgia, analgesic requirement, bleeding, mucosal recovery, and incidence of postoperative bleeding in patients undergoing uvulopalatopharyngoplasty. Design: A prospective double-blind randomized study. Setting: University-affiliated tertiary referral hospital. Participants: Eighty adult patients with obstructive sleep apnea syndrome requiring uvulopalatopharyngoplasty were recruited and randomly allocated into either a sucralfate treatment group or a control group. Interventions: All patients underwent uvulopalatopharyngoplasty. Patients enrolled in the sucralfate group (n=40) were instructed to gargle the sucralfate suspension and then to swallow. Patients enrolled in the control group (n=40) were instructed to gargle placebo suspension at the same doses and schedule. Main Outcome Measures: Postoperative throat pain, otalgia, amount of analgesic required, degree of strength (defined as patients' general well-being and return to regular daily activities), percentage of mucosal covering, and postoperative bleeding. Results: Throat pain and otalgia occurred significantly less often in sucralfate group, with less analgesic requirement and with rapid mucosal healing and early return to regular daily activities. There was no significant difference in episodes of postoperative bleeding between the 2 groups (P=.37). Conclusions: Although sucralfate therapy may not provide complete analgesia after uvulopalatopharyngoplasty, it may reduce the amount of analgesic required, thus preventing dose-related adverse effects from the analgesic agent. It can also significantly reduce the total number of days needed to return to normal daily activities (P=.41).
AB - Objective: To evaluate the effectiveness of sucralfate in influencing throat pain, otalgia, analgesic requirement, bleeding, mucosal recovery, and incidence of postoperative bleeding in patients undergoing uvulopalatopharyngoplasty. Design: A prospective double-blind randomized study. Setting: University-affiliated tertiary referral hospital. Participants: Eighty adult patients with obstructive sleep apnea syndrome requiring uvulopalatopharyngoplasty were recruited and randomly allocated into either a sucralfate treatment group or a control group. Interventions: All patients underwent uvulopalatopharyngoplasty. Patients enrolled in the sucralfate group (n=40) were instructed to gargle the sucralfate suspension and then to swallow. Patients enrolled in the control group (n=40) were instructed to gargle placebo suspension at the same doses and schedule. Main Outcome Measures: Postoperative throat pain, otalgia, amount of analgesic required, degree of strength (defined as patients' general well-being and return to regular daily activities), percentage of mucosal covering, and postoperative bleeding. Results: Throat pain and otalgia occurred significantly less often in sucralfate group, with less analgesic requirement and with rapid mucosal healing and early return to regular daily activities. There was no significant difference in episodes of postoperative bleeding between the 2 groups (P=.37). Conclusions: Although sucralfate therapy may not provide complete analgesia after uvulopalatopharyngoplasty, it may reduce the amount of analgesic required, thus preventing dose-related adverse effects from the analgesic agent. It can also significantly reduce the total number of days needed to return to normal daily activities (P=.41).
UR - http://www.scopus.com/inward/record.url?scp=33750155548&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33750155548&partnerID=8YFLogxK
M3 - Article
C2 - 17043255
AN - SCOPUS:33750155548
VL - 132
SP - 1082
EP - 1085
JO - JAMA Otolaryngology - Head and Neck Surgery
JF - JAMA Otolaryngology - Head and Neck Surgery
SN - 2168-6181
IS - 10
ER -